Hemodialysis and Peritoneal Dialysis Market

The global hemodialysis and peritoneal dialysis market is projected to reach USD 141.5 billion by 2031 from USD 102.7 billion in 2026, growing at a CAGR of 6.6% during the forecast period.

The primary growth driver for the global hemodialysis and peritoneal dialysis market is the worsening burden of chronic kidney disease and end-stage renal disease, both directly tied to rising rates of diabetes and hypertension across developed and developing economies. Aging populations in North America, Europe, and parts of Asia Pacific are adding structurally to the pool of patients who need long-term renal replacement therapy. Emerging markets across Southeast Asia, Latin America, and sub-Saharan Africa are contributing substantially to patient volumes as dialysis infrastructure expands and more countries integrate renal care into public health systems. Governments and payers in several high-burden markets have increased healthcare spending on dialysis access, lifting volumes at both in-center and home settings. Improved reimbursement frameworks in the US and parts of Europe have also reduced financial barriers that previously limited patient uptake of prescribed therapy.

To know about the assumptions considered for the study download the pdf brochure

Technology shifts are accelerating demand further. Automated peritoneal dialysis cyclers, home hemodialysis systems, and remote patient monitoring platforms have strengthened the clinical case for home-based treatment, offering patients greater flexibility while easing pressure on dialysis center capacity. Healthcare systems under cost-containment mandates increasingly view home dialysis as more sustainable than in-center care, a trend particularly evident in US value-based kidney care contracts. Manufacturers have also introduced next-generation dialysis machines with AI-assisted therapy management and automated pre-treatment functions, reducing the operational burden on clinical staff.

The prominent players in the hemodialysis and peritoneal dialysis market are Fresenius Medical Care (Germany), Vantive (US), B. Braun (Germany), Nipro Corporation (Japan), and Nikkiso Co., Ltd. (Japan), among others. These companies have pursued a mix of organic and inorganic strategies, including new product launches, manufacturing capacity expansion, technology partnerships, and acquisitions of dialysis consumable and equipment businesses. These efforts are directed at consolidating positions across the full dialysis value chain, from machines and consumables through to clinic services and digital care platforms.

In July 2025, Fresenius Medical Care (Germany) collaborated with the Coordination of National Institutes of Health and Specialty Hospital in Mexico to extend patient access to dialysis therapy. In October 2025, Vantive (US) collaborated with US Renal Care to expand access to home dialysis, with US Renal Care adopting Vantive's digitally enabled peritoneal dialysis products and services across 32 states. In December 2024, Nipro Corporation (Japan) acquired a dialysis reverse osmosis equipment manufacturing company in China, adding upstream manufacturing capacity in a key high-volume market. In December 2025, Nikkiso Co., Ltd. (Japan) launched the DBB-06 PRO hemodialysis machine for the US market, the first HD machine for that market to incorporate the company's D-FAS full-assist system, following FDA clearance in May 2025.

Fresenius Medical Care, headquartered in Bad Homburg, Germany, is the world's leading provider of products and services for people with renal diseases, treating more than 292,000 patients through a global network of approximately 3,600 dialysis centers as of December 31, 2025. The company operates around 35 production sites across all continents and manufactures dialysis machines, dialyzers, related disposables, reverse osmosis systems, and dialysate for in-center, home, and acute care settings. Key products include the 5008X CAREsystem hemodialysis machine, the Stay-Safe Harmony peritoneal dialysis cycler, and the NxStage home hemodialysis system. Fresenius Medical Care runs two operating segments: Care Delivery, which covers its clinic network and value-based kidney care through the Interwell Health subsidiary in the US, and Care Enablement, which covers its global products and equipment business. Research and development activities span sites in Germany, the US (Ogden, Utah), and China (Shanghai and Changshu).

Vantive, formerly the Baxter International Kidney Care segment, was launched as an independent company in February 2025 after its acquisition by funds managed by Carlyle Group for USD 3.8 billion. The company serves patients across more than 100 countries and had revenues of USD 4.5 billion in 2023 under its Baxter Kidney Care identity, with more than 23,000 employees globally. Its product portfolio covers peritoneal dialysis solutions and APD cyclers (including the Amia and Homechoice APD systems), hemodialysis machines and dialyzers (including the AK 98 machine and the Theranova dialyzer with MCO membrane technology for expanded hemodialysis, or HDx therapy), and CRRT systems for acute care (PrisMax). The Sharesource Connectivity Platform provides remote monitoring across Vantive's PD and home HD device range.

Market Ranking

The top five companies in the hemodialysis and peritoneal dialysis market are Fresenius Medical Care, Vantive, B. Braun, Nipro Corporation, and Nikkiso Co., Ltd.

Fresenius Medical Care holds the broadest integrated position, combining the largest global dialysis clinic network with a broad manufacturing base spanning machines, dialyzers, consumables, and fluids, as well as additional exposure to value-based care in the US through Interwell Health.

Vantive, operating as an independent company since February 2025, differentiates itself through its digitally integrated therapy ecosystem, in which the Sharesource remote monitoring platform connects APD cyclers to the Theranova MCO dialyzer, providing meaningful coverage across home dialysis and acute CRRT. B. Braun competes through its Avitum division, which spans hemodialysis machines (Dialog+ and Dialog iQ), dialysis concentrates, bloodlines, water treatment systems (AQUAboss nX), and a network of more than 360 dialysis and care centers across Europe, Asia Pacific, Africa, and Latin America.

Nipro Corporation draws competitive strength from its worldwide dialyzer market share, built on proprietary hollow-fiber membrane technology, and backed by a growing product range that includes dialysis machines, blood tubing sets, vascular access needles, peritoneal dialysis catheters, and dialysis information management software through its NephroFlow subsidiary.

Nikkiso Co., Ltd. holds more than 50% of the dialysis machine market in Japan and has expanded internationally with its DBB-series machines supporting HD, HDF, and single-needle modalities, with the DBB-06 PRO launch in December 2025 pushing the company into the US market in earnest. The broader competitive landscape includes regional manufacturers, Chinese OEM suppliers, and specialty dialysis service operators, with competition remaining particularly intense across the consumables and water treatment segments.

Related Reports:

Hemodialysis & Peritoneal Dialysis Market by Product (Hemodialysis Equipment, Dialysates, PD Machine, Consumables), Modality (CAPD, APD, SDHD, Conventional HD, Nocturnal HD), Disease Indication (CKD, ESRD, AKI), End User, Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]